Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Polyunsaturated fats (PUFAs), particularly omega-3 fatty acids found in fish oil (EPA and DHA), have been investigated for their role in supporting patients with congestive heart failure (CHF). The scientific evidence comes primarily from randomized controlled trials and meta-analyses. The most notable trial, GISSI-HF (2008), demonstrated a modest reduction in all-cause mortality and cardiovascular hospitalizations in patients with heart failure who received omega-3 supplementation. The American Heart Association and European Society of Cardiology have both issued statements acknowledging a potential, though limited, benefit for omega-3 PUFAs as adjunctive therapy in heart failure. The proposed mechanisms include anti-inflammatory effects, antiarrhythmic properties, and improvements in endothelial function. However, the magnitude of benefit is small, and some more recent studies and meta-analyses have questioned the clinical significance of these effects. Importantly, there is little evidence supporting the use of other polyunsaturated fats (such as omega-6 fatty acids) for CHF. Overall, while there is scientific support for the use of omega-3 PUFAs as an adjunct in CHF management, the strength of evidence is modest (rated 2/5), and their use should be considered supplementary to guideline-directed medical therapy rather than a replacement.

More about polyunsaturated fat
More about Congestive Heart Failure

Other ingredients used for Congestive Heart Failure

Other health conditions supported by polyunsaturated fat

Products containing polyunsaturated fat